알츠하이머병치매 조기진단 관련 별세포의 역할

키워드

참고문헌 (78)

1. Semyanov A, "Astrocytic processes : from tripartite synapses to the active milieu", Trends Neurosci, 44, pp.781~792 (2021)
2. Verkhratsky A, "Physiology of astroglia", Physiol Rev, 98, pp.239~389 (2018)
3. Simard M, "Signaling at the gliovascular interface", J Neurosci, 23, pp.9254~9262 (2003)
4. Kumar A, "Reactive astrogliosis : a friend or foe in the pathogenesis of Alzheimer’s disease", J Neurochem, 164, pp.309~324 (2023)
5. Danbolt NC, "Neuronal vs glial glutamate uptake : resolving the conundrum", Neurochem Int, 98, pp.29~45 (2016)
6. Pellerin L, "Sweet sixteen for ANLS", J Cereb Blood Flow Metab, 32, pp.1152~1166 (2012)
7. Allen NJ, "Cell biology of astrocyte-synapse interactions", Neuron, 96, pp.697~708 (2017)
8. Khakh BS, "Diversity of astrocyte functions and phenotypes in neural circuits", Nat Neurosci, 18, pp.942~952 (2015)
9. Pfrieger FW, "Cholesterol metabolism in neurons and astrocytes", Prog Lipid Res, 50, pp.357~371 (2011)
10. Escartin C, "Reactive astrocyte nomenclature, definitions, and future directions", Nat Neurosci, 24, pp.312~325 (2021)
11. Verkhratsky A, "Astroglial asthenia and loss of function, rather than reactivity, contribute to the ageing of the brain", Pflugers Arch, 473, pp.753~774 (2021)
12. Nichols NR, "GFAP mRNA increases with age in rat and human brain", Neurobiol Aging, 14, pp.421~429 (1993)
13. David JP, "Glial reaction in the hippocampal formation is highly correlated with aging in human brain", Neurosci Lett, 235, pp.53~56 (1997)
14. Popov A, "Mitochondrial malfunction and atrophy of astrocytes in the aged human cerebral cortex", Nat Commun, 14, pp.8380~ (2023)
15. Lalo U, "Agedependent remodelling of ionotropic signalling in cortical astroglia", Aging Cell, 10, pp.392~402 (2011)
16. Kumar MJ, "Perspectives on MAO-B in aging and neurological disease : where do we go from here?", Mol Neurobiol, 30, pp.77~89 (2004)
17. Zorec R, "Preventing neurodegeneration by adrenergic astroglial excitation", FEBS J, 285, pp.3645~3656 (2018)
18. Zorec R, "Adrenergic regulation of astroglial aerobic glycolysis and lipid metabolism : towards a noradrenergic hypothesis of neurodegeneration", Neurobiol Dis, 182, pp.106132~ (2023)
19. Verhoog QP, "Astrocytes as guardians of neuronal excitability : mechanisms underlying epileptogenesis", Front Neurol, 11, pp.591690~ (2020)
20. Capuani C, "Defective glutamate and K+ clearance by cortical astrocytes in familial hemiplegic migraine type 2", EMBO Mol Med, 8, pp.967~986 (2016)
21. Cotter DR, "Glial cell abnormalities in major psychiatric disorders : the evidence and implications", Brain Res Bull, 55, pp.585~595 (2001)
22. Cobb JA, "Density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder", Neuroscience, 316, pp.209~220 (2016)
23. Eastwood SL, "Markers of glutamate synaptic transmission and plasticity are increased in the anterior cingulate cortex in bipolar disorder", Biol Psychiatry, 67, pp.1010~1016 (2010)
24. Han F, "Loss of glial cells of the hippocampus in a rat model of post-traumatic stress disorder", Neurochem Res, 40, pp.942~951 (2015)
25. Soto JS, "Astrocyte-neuron subproteomes and obsessive-compulsive disorder mechanisms", Nature, 616, pp.764~773 (2023)
26. Katsel P, "Astrocyte and glutamate markers in the superficial, deep, and white matter layers of the anterior cingulate gyrus in schizophrenia", Neuropsychopharmacology, 36, pp.1171~1177 (2011)
27. Lu J, "S100B and APP promote a gliocentric shift and impaired neurogenesis in Down syndrome neural progenitors", PLoS One, 6, pp.e22126~ (2011)
28. Oria M, "Premature neural progenitor cell differentiation into astrocytes in retinoic acid-induced spina bifida rat model", Front Mol Neurosci, 15, pp.888351~ (2022)
29. Potokar M, "Impaired αGDI f unction in the X-linked intellectual disability : the impact on astroglia vesicle dynamics", Mol Neurobiol, 54, pp.2458~2468 (2017)
30. Okabe Y, "Alterations of gene expression and glutamate clearance in astrocytes derived from an MeCP2-null mouse model of Rett syndrome", PLoS One, 7, pp.e35354~ (2012)
31. Barbeito L, "Astrocyte-based cell therapy : new hope for amyotrophic lateral sclerosis patients?", Stem Cell Res Ther, 9, pp.241~ (2018)
32. Peteri UK, "Astrocytes in neuropathologies affecting the frontal cortex", Front Cell Neurosci, 13, pp.44~ (2019)
33. Wilhelmsson U, "Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury", Proc Natl Acad Sci U S A, 103, pp.17513~17518 (2006)
34. Heneka MT, "Neuroglia in neurodegeneration", Brain Res Rev, 63, pp.189~211 (2010)
35. Serrano-Pozo A, "Reactive glia not only associates with plaques but also parallels tangles in Alzheimer’s disease", Am J Pathol, 179, pp.1373~1384 (2011)
36. Lemoine L, "Cortical laminar tau deposits and activated astrocytes in Alzheimer’s disease visualised by 3H-THK5117 and 3H-deprenyl autoradiography", Sci Rep, 7, pp.45496~ (2017)
37. Yun SP, "Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease", Nat Med, 24, pp.931~938 (2018)
38. Octeau JC, "An optical neuron-astrocyte proximity assay at synaptic distance scales", Neuron, 98, pp.49~66 (2018)
39. McKay NS, "Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network(DIAN)", Nat Neurosci, 26, pp.1449~1460 (2023)
40. Tagarelli A, "Alois Alzheimer : a hundred years after the discovery of the eponymous disorder", Int J Biomed Sci, 2, pp.196~204 (2006)
41. Selkoe DJ, "The amyloid hypothesis of Alzheimer’s disease at 25 years", EMBO Mol Med, 8, pp.595~608 (2016)
42. Marutle A, "³H-deprenyl and ³H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain", J Neuroinflammation, 10, pp.861~ (2013)
43. Gaweska H, "Structures and mechanism of the monoamine oxidase family", Biomol Concepts, 2, pp.365~377 (2011)
44. Lesné S, "Transforming growth factor-β1 potentiates amyloid-β generation in astrocytes and in transgenic mice", J Biol Chem, 278, pp.18408~18418 (2003)
45. Rothstein JD, "Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate", Neuron, 16, pp.675~686 (1996)
46. Hardy J, "Region-specific loss of glutamate innervation in Alzheimer’s disease", Neurosci Lett, 73, pp.77~80 (1987)
47. Mitew S, "Altered synapses and gliotransmission in Alzheimer’s disease and AD model mice", Neurobiol Aging, 34, pp.2341~2351 (2013)
48. Verkhratsky A, "Astrocytes in human central nervous system diseases : a frontier for new therapies", Signal Transduct Target Ther, 8, pp.396~ (2023)
49. Cosenza-Nashat M, "Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohis tochemical localization in abnormal human brain", Neuropathol Appl Neurobiol, 35, pp.306~328 (2009)
50. Edison P, "In vivo imaging of glial activation in Alzheimer’s disease", Front Neurol, 9, pp.625~ (2018)
51. Lavisse S, "Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging", J Neurosci, 32, pp.10809~10818 (2012)
52. Fowler JS, "Selective reduction of radiotracer trapping by deuterium substitution : comparison of carbon-11-L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping", J Nucl Med, 36, pp.1255~1262 (1995)
53. SMBT-1 in imaging of monoamine oxidase-B, "ACS Chem Neurosci", 2022, 322~329
54. Villemagne VL, "First-in-humans evaluation of 18F-SMBT-1, a novel 18Flabeled monoamine oxidase-B PET tracer for imaging reactive astrogliosis", J Nucl Med, 63, pp.1551~1559 (2022)
55. Kumar A, "Astroglial tracer BU99008 detects multiple binding sites in Alzheimer’s disease brain", Mol Psychiatry, 26, pp.5833~5847 (2021)
56. Tyacke RJ, "Evaluation and initial in vitro and ex vivo characterization of the potential positron emission tomography ligand, BU99008(2-(4, 5-dihydro-1H-imidazol-2-yl)-1-methyl-1H-indole), for the imidazoline2 binding site", Synapse, 66, pp.542~551 (2012)
57. Kumlien E, "PET with 11C-deuterium-deprenyl and 18F-FDG in focal epilepsy", Acta Neurol Scand, 103, pp.360~366 (2001)
58. Engler H, "Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease", Eur J Nucl Med Mol Imaging, 30, pp.85~95 (2003)
59. (L)-deprenyl-D2 PET, "J Neurol Sci", 2007, 17~22
60. Carter SF, "Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl : a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG", J Nucl Med, 53, pp.37~46 (2012)
61. Schöll M, "Early astrocytosis in autosomal dominant Alzheimer’s disease measured in vivo by multi-tracer positron emission tomography", Sci Rep, 5, pp.16404~ (2015)
62. Rodriguez-Vieitez E, "Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease", Brain, 139(Pt 3), pp.922~936 (2016)
63. Carter SF, "Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer’s disease", Eur J Nucl Med Mol Imaging, 46, pp.348~356 (2019)
64. Harada R, "18F-SMBT-1 : a selective and reversible PET tracer for monoamine oxidase-B imaging", J Nucl Med, 62, pp.253~258 (2021)
65. Villemagne VL, "Assessing reactive astrogliosis with 18F-SMBT-1 across the Alzheimer disease spectrum", J Nucl Med, 63, pp.1560~1569 (2022)
66. Tyacke RJ, "Evaluation of(11)C-BU99008, a PET ligand for the imidazoline(2)binding site in human brain", J Nucl Med, 59, pp.1597~1602 (2018)
67. Calsolaro V, "Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using 11C-BU99008 PET and its relationship with amyloid load", Mol Psychiatry, 26, pp.5848~5855 (2021)
68. Choo IL, "Astrocytosis measured by ¹¹C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer’s patients", Eur J Nucl Med Mol Imaging, 41, pp.2120~2126 (2014)
69. Vilaplana E, "Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease", Neurology, 94, pp.e2026~e2036 (2020)
70. Millar PR, "Advanced structural brain aging in preclinical autosomal dominant Alzheimer disease", Mol Neurodegener, 18, pp.98~ (2023)
71. Fukuyama R, "The cerebrospinal fluid level of glial fibrillary acidic protein is increased in cerebrospinal fluid from Alzheimer’s disease patients and correlates with severity of dementia", Eur Neurol, 46, pp.35~38 (2001)
72. Ishiki A, "Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration", J Neurochem, 136, pp.258~261 (2016)
73. Pereira JB, "Plasma GFAP is an early marker of amyloid-βbut not tau pathology in Alzheimer’s disease", Brain, 144, pp.3505~3516 (2021)
74. Chiotis K, "Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multimodal PET and plasma GFAP", Mol Neurodegener, 18, pp.60~ (2023)
75. Bellaver B, "Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease", Nat Med, 29, pp.1775~1781 (2023)
76. Bucci M, "Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic", Transl Psychiatry, 13, pp.268~ (2023)
77. Peskind ER, "Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer’s disease", Neurochem Int, 39, pp.409~413 (2001)
78. Chaves ML, "Serum levels of S100B and NSE proteins in Alzheimer’s disease patients", J Neuroinflammation, 7, pp.6~ (2010)

관련 논문AI추천